Total Payments
$26,582
2024 Payments
$621.14
Companies
29
Transactions
392
Medicare Patients
13,973
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$19,800 (74.5%)
Food & Beverage$6,603 (24.8%)
Education$178.23 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,800 | 13 | 74.5% |
| Food and Beverage | $6,603 | 376 | 24.8% |
| Education | $178.23 | 3 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21,601 | 91 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $877.71 | 67 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $811.55 | 87 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $562.31 | 29 | $0 (2024) |
| Amgen Inc. | $487.78 | 26 | $0 (2024) |
| PFIZER INC. | $263.22 | 16 | $0 (2024) |
| Boston Scientific Corporation | $198.36 | 4 | $0 (2024) |
| Amarin Pharma Inc. | $191.25 | 9 | $0 (2021) |
| Astellas Pharma US Inc | $183.09 | 3 | $0 (2019) |
| HeartFlow, Inc. | $146.09 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $621.14 | 46 | E.R. Squibb & Sons, L.L.C. ($218.75) |
| 2023 | $513.02 | 18 | HeartFlow, Inc. ($146.09) |
| 2022 | $200.64 | 10 | Janssen Pharmaceuticals, Inc ($87.58) |
| 2021 | $588.31 | 40 | Janssen Pharmaceuticals, Inc ($350.70) |
| 2020 | $543.76 | 25 | Janssen Pharmaceuticals, Inc ($147.81) |
| 2019 | $1,306 | 94 | Novartis Pharmaceuticals Corporation ($253.34) |
| 2018 | $6,394 | 63 | Novartis Pharmaceuticals Corporation ($5,424) |
| 2017 | $16,415 | 96 | Novartis Pharmaceuticals Corporation ($15,754) |
All Payment Transactions
392 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $25.48 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $3.86 | General |
| Category: Cardiovascular | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.38 | General |
| Category: Cardiovascular | ||||||
| 10/11/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Cardiology | ||||||
| 09/26/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.32 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Cardiology | ||||||
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.36 | General |
| Category: Cardiovascular | ||||||
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $0.19 | General |
| Category: Cardiovascular | ||||||
| 08/28/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Cardiology | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $6.11 | General |
| Category: Cardiovascular | ||||||
| 08/09/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.20 | General |
| Category: Cardiovascular | ||||||
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $5.99 | General |
| Category: Cardiovascular | ||||||
| 07/25/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $25.16 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.24 | General |
| Category: Cardiovascular | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $2.22 | General |
| Category: Cardiovascular | ||||||
| 05/31/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Cardiology | ||||||
| 05/09/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $25.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.15 | General |
| Category: Cardiovascular | ||||||
| 04/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.66 | General |
| Category: Cardiovascular | ||||||
| 04/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $45.00 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 3,032 | 4,361 | $1.4M | $398,811 |
| 2022 | 23 | 3,129 | 4,622 | $1.4M | $397,594 |
| 2021 | 26 | 3,843 | 5,929 | $1.7M | $493,735 |
| 2020 | 23 | 3,969 | 5,778 | $1.6M | $429,239 |
Total Patients
13,973
Total Services
20,690
Medicare Billing
$1.7M
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 433 | 615 | $196,980 | $78,769 | 40.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 222 | 223 | $301,300 | $75,458 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 523 | 790 | $197,550 | $73,440 | 37.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 223 | 441 | $86,325 | $39,827 | 46.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 155 | 624 | $93,600 | $26,691 | 28.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 155 | 171 | $142,785 | $23,784 | 16.7% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 23 | 24 | $23,000 | $16,197 | 70.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 226 | 229 | $87,020 | $11,082 | 12.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 60 | 60 | $27,000 | $9,463 | 35.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 625 | 748 | $44,880 | $7,652 | 17.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 70 | $26,250 | $6,615 | 25.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 40 | $19,000 | $5,493 | 28.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 36 | 37 | $31,080 | $5,284 | 17.0% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 22 | 22 | $26,810 | $5,014 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 61 | $12,200 | $4,036 | 33.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $10,150 | $3,718 | 36.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 41 | $12,300 | $2,537 | 20.6% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 33 | 34 | $11,900 | $1,802 | 15.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 21 | 21 | $9,735 | $1,030 | 10.6% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 24 | 25 | $5,000 | $506.00 | 10.1% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 26 | 26 | $2,700 | $255.25 | 9.5% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2023 | 16 | 16 | $320.00 | $100.07 | 31.3% |
| 85610 | Blood test, clotting time | Office | 2023 | 13 | 14 | $210.00 | $58.80 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 671 | 1,126 | $281,500 | $103,014 | 36.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 226 | 228 | $307,900 | $80,576 | 26.2% |
About Dr. Gregory Petro, MD
Dr. Gregory Petro, MD is a Cardiovascular Disease healthcare provider based in Mcdonough, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124023304.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Petro, MD has received a total of $26,582 in payments from pharmaceutical and medical device companies, with $621.14 received in 2024. These payments were reported across 392 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,800).
As a Medicare-enrolled provider, Petro has provided services to 13,973 Medicare beneficiaries, totaling 20,690 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Mcdonough, GA
- Active Since 06/15/2005
- Last Updated 02/22/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1124023304
Products in Payments
- ENTRESTO (Drug) $21,562
- XARELTO (Drug) $974.42
- ELIQUIS (Drug) $773.99
- Repatha (Biological) $416.05
- BRILINTA (Drug) $336.68
- FARXIGA (Drug) $213.46
- Vascepa (Drug) $191.25
- RESONATE (Device) $162.99
- FFRct (Device) $146.09
- Impella (Device) $133.75
- CAMZYOS (Drug) $132.52
- NORTHERA (Drug) $114.20
- PRALUENT (Drug) $109.48
- LifeVest (Device) $96.28
- CHANTIX (Drug) $94.13
- VERQUVO (Drug) $76.11
- OPSUMIT (Drug) $74.24
- Corlanor (Drug) $71.73
- JARDIANCE (Drug) $56.69
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) $47.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Mcdonough
Dr. Akshay Gupta, Md, MD
Cardiovascular Disease — Payments: $52,442
Cardiovascular Disease $52,442
John Smith, Md, MD
Cardiovascular Disease — Payments: $9,683
Cardiovascular Disease $9,683
Homayoun Amin, M.d, M.D
Cardiovascular Disease — Payments: $8,366
Cardiovascular Disease $8,366
Dr. Srinivasa Chennareddy, M.d, M.D
Cardiovascular Disease — Payments: $7,696
Cardiovascular Disease $7,696
Mrs. Camille Nelson, Md, MD
Cardiovascular Disease — Payments: $5,650
Cardiovascular Disease $5,650
Rajasekhar Reddy, M.d, M.D
Cardiovascular Disease — Payments: $5,199
Cardiovascular Disease $5,199